The global fertility tourism market size is expected to be valued at US$ 2.6 billion in 2026 and projected to reach US$ 7.3 billion, growing at a CAGR of 15.6% between 2026 and 2033. The market is experiencing rapid growth as individuals and couples increasingly travel across borders to access affordable, advanced, and timely fertility treatments.

The market is further driven by rising infertility rates, delayed parenthood, increasing acceptance of assisted reproductive technologies (ART), and significant differences in treatment costs, availability, and regulatory frameworks across countries. Leading destinations attract international patients through specialized clinics, experienced fertility specialists, advanced reproductive procedures, and comprehensive medical travel support services. The market includes treatments such as in vitro fertilization (IVF), intrauterine insemination (IUI), egg and sperm donation, surrogacy where legally permitted, and fertility preservation services.

Drivers - Soaring Domestic Treatment Costs Driving Cross-Border Fertility Care Demand

The high cost of fertility treatments in high-income markets, particularly the U.S., the United Kingdom, Australia, and Canada, remains one of the major drivers pushing patients toward cross-border fertility care destinations. A single IVF cycle in the U.S. costs between US$ 12,000 and US$ 20,000 on average, excluding medications that add another US$ 3,000 to 6,000, according to the American Society for Reproductive Medicine (ASRM). In contrast, equivalent treatment in Spain, the Czech Republic, India, and Thailand is available at 40 to 70% lower cost while maintaining internationally recognized clinical standards.

The U.S. Centers for Disease Control and Prevention (CDC) reports that only a minority of U.S. states mandate insurance coverage for fertility treatments, leaving most patients to fund treatment entirely out of pocket. This financial burden makes international treatment a practical and affordable option for a growing patient population. The persistent cost advantage across destination markets continues to generate stable demand for fertility tourism as healthcare costs rise in major source countries.

Rising Global Infertility Rates and Changing Social Demographics

Declining fertility rates, delayed parenthood, increasing prevalence of conditions including polycystic ovary syndrome (PCOS), endometriosis, and male factor infertility, together with growing family formation among same-sex couples and single parents, continue to expand the global patient pool seeking fertility treatment. The WHO's 2023 infertility prevalence study, the first comprehensive global assessment of its kind, confirmed that 17.5% of the global adult population is affected by infertility, highlighting its significance as a major public health issue.

Delayed childbearing remains another key growth factor. According to the U.S. National Center for Health Statistics, the average age of first-time mothers in the U.S. increased from 21.4 years in 1970 to 27.0 years in 2022, increasing demand for assisted reproductive technologies as age-related fertility decline becomes more common. Countries including Spain, the Czech Republic, and Thailand have adopted regulatory frameworks that accommodate international patients through services such as anonymous egg donation and fertility treatment for same-sex couples, creating a regulatory advantage alongside cost benefits for cross-border fertility care.

Restraints – Complex Regulatory and Legal Differences Across Destination Countries

Significant differences in fertility treatment regulations across destination countries, including donor anonymity, surrogacy laws, embryo storage limits, and donor compensation policies, create a fragmented legal environment that increases patient uncertainty, legal complexity, and operational risks for fertility tourism providers. Countries including India and Thailand have introduced legislative changes restricting commercial surrogacy for foreign nationals, abruptly closing treatment pathways previously used by thousands of international patients and highlighting the regulatory uncertainty that affects destination market stability. Frequent policy changes increase investment risk for fertility clinics and reduce patient confidence in long-term treatment planning, particularly when regulatory changes interrupt treatment cycles or complicate legal recognition of reproductive procedures.

Emotional, Physical, and Logistical Challenges of Cross-Border Treatment

Despite the strong financial benefits of fertility tourism, the emotional, physical, and logistical demands associated with cross-border reproductive care continue to limit adoption among many patients. A standard IVF cycle requires multiple clinical visits over four to six weeks for hormonal monitoring, egg retrieval, embryo transfer, and follow-up care, making international travel both physically demanding and logistically complex while patients manage work responsibilities and the emotional stress of fertility treatment.

The European Society of Human Reproduction and Embryology (ESHRE) reports that cross-border reproductive care patients experience higher anxiety levels than domestic patients due to communication barriers, unfamiliar healthcare systems, and limited continuity of care between clinicians in home and destination countries. These challenges are particularly significant among older patients, who represent one of the largest fertility treatment groups, reinforcing the need for coordinated care models, remote consultations, and comprehensive patient support services.

Opportunities – Cryopreservation and Fertility Preservation Emerging as High-Growth Segments

The rapid adoption of elective egg and embryo cryopreservation, driven by individuals prioritizing career development or delayed family planning, represents one of the significant opportunities in the fertility tourism market. The American Society for Reproductive Medicine (ASRM) removed the "experimental" designation from oocyte cryopreservation in 2012, and social egg-freezing cycles across Europe and North America have since recorded sustained double-digit growth. ESHRE data indicates that egg-freezing procedures across European clinics increased by over 300% during the past decade.

Major companies including Apple, Meta, and Google have incorporated egg-freezing benefits into employee healthcare programs, increasing awareness and adoption among working professionals. Destination markets including Spain, the Czech Republic, and Greece offer egg-freezing and donor egg programs at 50 to 65% lower cost than the U.S. and Australia while maintaining comparable laboratory standards, strengthening their appeal for international fertility preservation. Clinics offering integrated cryopreservation services, remote monitoring, international embryo transport, and transparent pricing continue to strengthen their competitive position in this rapidly expanding market.

Opportunities – Digital Health Platforms and Fertility Tourism Facilitators Expanding Patient Access

The emergence of digital health platforms, telemedicine-enabled fertility consultation services, and specialized fertility tourism facilitators is reducing the information and access barriers that previously limited cross-border reproductive care to affluent and well-connected patients. AI-powered clinic matching, multilingual patient support, remote hormonal monitoring, and transparent price comparison are transforming fertility tourism into a more accessible and transparent healthcare service. The International Society of Travel Medicine (ISTM) identifies the integration of medical tourism platforms with fertility-specific concierge services as a major trend in the internationalization of reproductive healthcare.

Fertility clinic networks such as IVI RMA Global, operating over 80 clinics across 13 countries, and Virtus Health continue investing in digital patient management platforms that support remote consultations, treatment monitoring, and post-treatment follow-up across borders. These integrated digital ecosystems provide multinational clinic networks with a competitive advantage over standalone providers while expanding access to cross-border fertility care for patients across Asia Pacific, Latin America, and other emerging markets.

Treatment Type Insights

In vitro fertilization (IVF) represents the dominant treatment type, commanding about 29% of the fertility tourism market share in 2026, reflecting its position as the most clinically established and widely used assisted reproductive technology for couples and individuals with complex infertility conditions where simpler interventions have proven unsuccessful. The European IVF-Monitoring Consortium (EIM) under ESHRE reports that IVF and ICSI together account for the majority of all assisted reproductive technology cycles performed across European clinics, highlighting the procedure's dominant clinical volume in the primary fertility tourism destination region.

IVF's leadership in cross-border fertility care is further supported by the substantial cost difference between source and destination countries. A single IVF cycle costs between US$ 3,000 and 6,000 in the Czech Republic and Spain compared with US$ 15,000 and 20,000 in the U.S., making IVF the treatment that delivers the greatest financial benefit through medical travel.

Cryopreservation represents the fastest-growing treatment segment, driven by rising adoption of elective egg freezing among career-focused women, increasing awareness of fertility preservation, and its growing acceptance as a proactive reproductive healthcare decision rather than a treatment reserved for medical necessity. In addition, the availability of affordable fertility preservation services in leading medical tourism destinations is attracting more international patients seeking long-term reproductive planning.

Application Insights

Fertility clinics are projected to hold the largest market share of 52% in 2026, supported by strong patient preference for specialized reproductive care centers over general hospitals when seeking complex and highly personalized fertility treatments. Dedicated fertility clinics offer significant advantages, including specialized reproductive medicine teams, high-volume embryology laboratories associated with improved clinical outcomes, patient-centered treatment environments, and access to advanced technologies such as time-lapse embryo monitoring and preimplantation genetic testing (PGT). Leading clinics including IVI RMA Global, Monash IVF Group, Genea Fertility, and Bourn Hall Fertility Clinic demonstrate that specialized fertility centers remain the preferred choice for international patients seeking high-quality reproductive care.

Medical tourism facilitators represent the fastest-growing application segment as digital platforms simplify cross-border fertility care through AI-enabled clinic matching, transparent pricing, multilingual patient support, and coordinated treatment planning, making international fertility services more accessible to a broader global patient population. The growing complexity of fertility regulations and the need for trusted healthcare navigation services further strengthen demand for specialized facilitators.

North America Fertility Tourism Market Trends and Insights

North America is anticipated to lead the global fertility tourism market with around 37% share in 2026, owing to its position as the world's largest patient source region rather than a major treatment destination. High domestic IVF costs, inconsistent insurance coverage across the U.S., and restrictions related to donor anonymity encourage significant outbound patient movement toward Europe and Asia Pacific. At the same time, Canada is emerging as an attractive destination for U.S. patients seeking more affordable fertility care under a similar regulatory framework. The regional market outlook is shaped by expanding employer-sponsored fertility benefits, increasing awareness of international treatment options, and the adoption of digital platforms that simplify access to overseas fertility clinics.

U.S. Fertility Tourism Market Insights

The U.S. accounts for about 90% of the North American fertility tourism market revenue, driven mainly by outbound medical travel as patients seek IVF, egg donation, and surrogacy services at 40 to 70% lower costs in destinations such as Spain, the Czech Republic, India, and Thailand. According to RESOLVE: The National Infertility Association, only 19 states in the U.S. mandate insurance coverage for fertility treatments, leaving many patients responsible for significant out-of-pocket expenses. Rising treatment costs, limited insurance support, and increasing awareness of international fertility options continue to support outbound patient growth from the U.S.

Europe Fertility Tourism Market Trends and Insights

Europe is projected to hold nearly 30% share of the market in 2026, serving as both a major source and destination region. Patients from countries such as the U.K., Germany, France, and Ireland frequently travel to Spain, the Czech Republic, and Greece for treatments that are restricted, unavailable, or more expensive in their home countries. The region benefits from internationally recognized fertility clinics, strong clinical expertise, established regulatory frameworks, and treatment costs below North American levels. ESHRE data consistently identifies Spain as one of the leading destinations for cross-border egg donation treatments.

Germany Fertility Tourism Market Insights

Germany contributes roughly 18% of the European fertility tourism market revenue, primarily serving as a source market where patients travel abroad due to domestic restrictions under the German Embryo Protection Act. Limitations on anonymous egg donation and certain embryo transfer practices encourage German patients to seek fertility treatments in destinations such as Spain, the Czech Republic, and Denmark, where broader treatment options are available. Germany remains one of Europe's largest outbound fertility patient markets, with demand supported by increasing awareness of international treatment alternatives through digital healthcare platforms.

U.K. Fertility Tourism Market Insights

The U.K. is expected to hold a significant share of the European market in 2026, supported by increasing outbound patient demand due to long NHS waiting periods for funded IVF cycles, high private treatment costs, and limited access to certain donor services. Private IVF treatments in the U.K. typically cost £5,000 to £8,000 per cycle, while countries such as Spain attract patients through lower costs and broader donor availability, including anonymous egg donation options that remain restricted under U.K. regulations. The Human Fertilisation and Embryology Authority (HFEA) has reported rising interest among patients exploring overseas fertility treatment options. Continued pressure on NHS fertility services is expected to sustain outbound fertility travel throughout the projection period.

France Fertility Tourism Market Insights

France is anticipated to hold a considerable share of the European market in 2026, with outbound fertility travel driven by historical restrictions on donor services and limited treatment accessibility. The 2021 Bioethics Law expanded IVF access to single women and same-sex couples; however, donor shortages continue to encourage some patients to seek treatment abroad. French patients commonly travel to Spain and Belgium for donor egg and sperm treatments. Expanding domestic donor recruitment programs may reduce outbound demand over time, although international fertility services remain an important option for patients seeking faster access.

Asia Pacific Fertility Tourism Market Trends and Insights

Asia Pacific represents the fastest-growing market for fertility tourism, supported by expanding fertility clinic infrastructure in Thailand, India, Malaysia, and Singapore, increasing infertility awareness among the growing middle-class population, and rising inbound patient flows from Australia, New Zealand, and East Asia. China's large infertility population, estimated at over 50 million couples by the National Health Commission of China, combined with limited domestic treatment availability, creates strong demand for overseas fertility services. Thailand and Malaysia are emerging as important regional destinations due to competitive treatment costs and expanding reproductive healthcare capabilities.

India Fertility Tourism Market Insights

India is expected to hold a substantial share of the Asia Pacific fertility tourism market in 2026, functioning as both a major inbound destination and a rapidly expanding domestic fertility market. Competitive IVF costs of US$ 2,000 to US$ 3,500 per cycle attract patients from Europe, the Middle East, and Africa seeking affordable reproductive care. Leading clinic networks including Indira IVF, Nova IVF Fertility, and Apollo Fertility are expanding service capabilities and international outreach.

The introduction of the National ART Registry under the Assisted Reproductive Technology (Regulation) Act, 2021, provides greater regulatory structure and improves confidence among international patients. India's market is expected to experience strong growth in the coming years, supported by cost advantages, expanding healthcare infrastructure, and increasing global patient awareness.

The global fertility tourism market is highly competitive, with providers differentiating through advanced assisted reproductive technologies, treatment affordability, success rates, and regulatory advantages. Fertility clinics across major destinations focus on expanding IVF capabilities, improving laboratory infrastructure, and offering personalized fertility solutions for international patients. Competition is shaped by factors such as experienced specialists, availability of egg and sperm donation services, shorter waiting periods, and medical travel support. Many providers are strengthening their global presence through partnerships, digital consultations, and patient-focused packages combining treatment with travel assistance.

Key Industry Developments

• In March 2025, Korean Medical Center (KMC) introduced its ‘most advanced’ fertility center in Qatar. KMC is committed to providing couples with individualized holistic treatment and all-encompassing support as they embark on their path toward parenthood.
• In October 2024, Burjeel Holdings launched a new facility called the Trust Fertility Clinic to support families battling fertility challenges at Burjeel Medical City, Abu Dhabi. It is anticipated to be the largest fertility center in the UAE, providing a wide range of treatments catering to individual needs of patients.